OakChart

NervGen Pharma Corp

NGENHealthcare·Biotechnology·Canada·Micro·NASD·Nov 11 • 3:36 PM ET

1.34+0.01 (0.75%)
2026-11-11 21:36 CET
Market cap
143.13 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-15.73 USD m
Free cash flow, TTM
-18.43 USD m
EPS diluted, TTM
-0.40
P/E
-
Compare

Price

NGEN against its 20, 50 and 200-day averages
2050200beatmiss
2.003.004.006.2M12.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NGENclose 1.3420-day 1.4350-day 1.76200-day 2.691.34

78.7% under the 52-week high of 6.30 on 8 Jan 2026. 52-week low 1.28 on 3 Nov 2026. Last 15 sessions, 21.1% high to low

Volume 0.41× normal · the line is the 50-bar volume average

Profile

NGEN
52-week range, 1% of the way up
1.286.30

NervGen Pharma Corp. operates as a clinical stage biotech company. It engages in the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

Employees8
IPOApr 03, 2019
Beta0.78
ATR, 14d0.10
Rel volume0.41
Short float5.41%
Insider own16.53%
Inst own12.09%

Snapshot

6 groups

Valuation

Index-
Market Cap144.21M
Enterprise Value83.04M
Income-15.73M
Sales0.00M
Book/sh0.31
Cash/sh0.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOApr 03, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.32
P/C2.36
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.07
Current Ratio2.07
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.40
EPS next Y-0.40
EPS next Q-0.10
EPS this Y-19.11%
EPS next Y23.08%
EPS next 5Y5.80%
EPS past 3/5Y-13.03% -10.94%
Sales past 3/5Y- -
EPS Y/Y TTM18.13%
Sales Y/Y TTM-
EPS Q/Q-1.20%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.-337.95% -

Ownership

Insider Own16.53%
Insider Trans0.00%
Inst Own12.09%
Inst Trans13.67%
ROA-41.42%
ROE-97.30%
ROIC-47.66%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-6.24%
SMA50-23.82%
SMA200-50.21%
Trades-

Technical

Shs Outstand106.41M
Shs Float89.82M
Short Float5.41%
Short Ratio9.57
Short Interest4.86M
52W High6.30 -78.73%
52W Low1.28 4.69%
Volatility6.07% 6.86%
ATR (14)0.10
RSI (14)34.59
Beta0.78
Rel Volume0.41
Avg Volume508.17K
Volume195,791

Performance

Perf Week-0.74%
Perf Month-17.79%
Perf Quarter-23.86%
Perf Half Y-63.19%
Perf YTD-76.07%
Perf Year-44.49%
Perf 3Y-1.47%
Perf 5Y-42.49%
Perf 10Y-
Recom1.00
Target Price10.00
Prev Close1.33
Price1.34
Change %0.75%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Jul 13, 2026InitiatedLLeerink PartnersOutperform$10+646.3%
Jun 11, 2026InitiatedTTD CowenBuy
Apr 27, 2026InitiatedHH.C. WainwrightBuy$18+1,243.3%

Peers

Mkt cap
TickerCompanyMkt cap
LCTXLineage Cell Therapeutics Inc284.52M
CLNNClene Inc62.64M
ACIUAC Immune SA231.61M
AVXLAnavex Life Sciences Corp98.72M
ACOGAlpha Cognition Inc191.21M
VYGRVoyager Therapeutics Inc108.90M
ALECAlector Inc401.60M
CGTXCognition Therapeutics Inc64.36M
ANNXAnnexon Inc795.44M
SLDBSolid Biosciences Inc847.76M

Held by

AUM
TickerCompanyAUM
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
IBRNiShares Neuroscience and Healthcare ETFAUM: 8.68M

News

latest 14 of 40
  • NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury (GlobeNewswire)
  • NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments (GlobeNewswire)
  • NervGen to Host Inaugural R&D Day on September 30, 2026 (GlobeNewswire)
  • NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study (GlobeNewswire)
  • NervGen Announces Pricing of US$60.0 Million Public Offering of Securities (GlobeNewswire) -43.48%
  • NervGen Announces Proposed Public Offering of Securities (GlobeNewswire)
  • NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer (GlobeNewswire)
  • NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
  • NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia (GlobeNewswire) -9.57%
  • NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
  • NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange (GlobeNewswire) -6.98%
  • NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs (GlobeNewswire) +8.10%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.265-0.061-0.2700.000.006
2026Q12026-05-15-0.015-0.074-0.0150.000.006
2025Q42026-03-31-0.258-0.114-0.2510.000.004
2025Q32025-11-25-0.043-0.061-0.0410.000.002
2026Q3---0.103--0.002
2026Q4---0.124--0.002
2027Q1---0.092---1
2027Q2---0.099---1
2027Q3---0.106---1
2027Q4---0.099---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-0.256-0.219-0.2630.000.00
2025FY-0.437-0.217-0.3130.000.00
2026FY--0.521--0.00
2027FY--0.401--0.00
2028FY--0.365--0.00
2029FY--0.220--65.97
2030FY-0.542--217.39

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-262000.000.000.00
2026Q3S2026-08-233000.000.000.00
2026Q3S2026-08-134000.000.000.00
2026Q3S2026-08-024000.000.000.00
2026Q3S2026-07-105000.000.000.00
2026Q3S2026-06-204000.000.000.00
2026Q3S2026-06-104010.000.000.00
2026Q3S2026-05-153010.000.000.00
2026Q3S2026-04-243010.000.000.00
2026Q3S2026-04-132010.000.000.00
2026Q3S2026-04-061010.000.000.00
2026Q3S2026-03-311100.010.010.01
2026Q3S2025-11-251000.000.000.00
2026Q3S2025-11-111000.000.000.00

Estimate history

EPS, annual0-0.039-0.284-0.26-0.258-0.302-0.28-0.263-0.437-0.4
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.082-0.055-0.088-0.039-0.091-0.041-0.251-0.015-0.093
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual27.20227.20229.35235.16846.1958.77959.60670.33379.649106.413
Period201720182019202020212022202320242025MRQ
Shares, quarterly70.04370.18570.33370.93872.83673.40879.64980.991106.413
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.040.040.060.110.090.030.030.030.02
Gross Profit-0.04-0.04-0.06-0.11-0.09-0.03-0.03-0.03-0.02
Selling, General and Administrative Excl. Other23.0917.9118.3213.0617.6010.188.327.411.03
Research and Development14.959.9111.505.9312.735.454.574.860.60
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-23.13-17.95-18.38-13.17-17.69-10.22-8.35-7.43-1.05
Interest Expense0.000.000.00-0.400.000.000.000.00
Unusual Expense-5.7813.570.103.70-1.470.000.00--
Net Income Before Taxes-15.73-31.57-17.70-16.58-15.92-10.15-8.34-7.36-1.05
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-15.73-31.57-17.70-16.58-15.92-10.15-8.34-7.36-1.05
Net Income From Continuing Operations-15.73-31.57-17.70-16.58-15.92-10.15-8.34-7.36-1.05
Net Income-15.73-31.57-17.70-16.58-15.92-10.15-8.34-7.36-1.05
EPS (Recurring)-0.35-0.31-0.26-0.24-0.32-0.26-0.26-0.28-0.04
EPS (Basic, Before Extraordinaries)-0.22-0.44-0.26-0.28-0.30-0.26-0.26-0.28-0.04
EPS (Diluted)-0.40-0.44-0.26-0.28-0.30-0.26-0.26-0.28-0.04
EBITDA-23.09-17.91-18.32-13.06-17.60-10.18-8.32-7.41-1.03
Non-Operating Income (Expense)1.62-0.050.780.290.700.070.010.070.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.673.864.414.482.133.202.550.970.03
Shares Outstanding106.4179.6570.3359.6158.7846.1935.1729.3527.20
Market Capitalization143.13143.13153.27121.3969.8358.4136.4133.0632.23

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other8.565.484.584.474.664.204.865.24
Research and Development5.623.542.573.221.952.193.273.19
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-8.57-5.49-4.59-4.48-4.67-4.21-4.87-5.25
Interest Expense0.000.000.000.00----
Unusual Expense-14.69-4.1714.52-1.441.95-1.391.50-1.29
Net Income Before Taxes7.80-1.22-19.30-3.02-6.57-2.75-6.16-3.83
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income7.80-1.22-19.30-3.02-6.57-2.75-6.16-3.83
Net Income From Continuing Operations7.80-1.22-19.30-3.02-6.57-2.75-6.16-3.83
Net Income7.80-1.22-19.30-3.02-6.57-2.75-6.16-3.83
EPS (Recurring)-0.19-0.05-0.12-0.06-0.07-0.05-0.07-0.07
EPS (Basic, Before Extraordinaries)0.08-0.02-0.25-0.04-0.09-0.04-0.09-0.05
EPS (Diluted)-0.09-0.02-0.25-0.04-0.09-0.04-0.09-0.05
EBITDA-8.56-5.48-4.58-4.47-4.66-4.20-4.86-5.24
Non-Operating Income (Expense)1.680.10-0.190.020.040.060.210.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.590.690.580.811.461.021.201.19
Shares Outstanding106.4180.9979.6573.4172.8470.9470.3370.19
Market Capitalization143.13300.07438.85173.05183.18141.82153.27133.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments16.1112.078.8416.5713.404.393.171.810.00
Short Term Receivables0.060.290.190.020.050.050.090.020.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.470.860.460.490.340.421.560.040.00
Total Current Assets16.6313.229.4917.0813.794.874.821.870.00
Net Property, Plant & Equipment0.000.000.150.220.000.000.000.000.00
Total Investments and Advances0.000.010.000.000.000.000.000.000.00
Intangible Assets0.300.320.390.320.370.370.390.400.00
Other Assets0.000.000.000.000.000.000.000.000.07
Total Assets16.9313.5510.0417.6214.175.245.222.270.07
Short Term Debt Incl. Current Port. of LT Debt0.010.070.070.060.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities14.3911.6811.417.480.850.590.710.330.08
Total Current Liabilities14.4011.7511.487.540.850.590.710.330.08
Long Term Debt0.000.010.080.150.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.100.00
Total Liabilities14.4011.7611.567.690.850.590.710.430.08
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2.541.79-1.529.9313.314.654.501.84-0.01
Total Shareholders Equity2.541.79-1.529.9313.314.654.501.84-0.01
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.541.79-1.529.9313.314.654.501.84-0.01
Total Liabilities & Stockholders Equity16.9313.5510.0417.6214.175.245.222.270.07
Book Value Per Share0.030.03-0.030.170.290.130.150.07-0.00
Tangible Book Value Per Share0.030.02-0.030.160.280.120.140.05-0.00
Full-Time Employees8-1611181813--
Price to Book Ratio4.2922.5232.145.2113.388.228.988.75-
Return on Assets-207.17-150.09-119.91-100.15-104.61-159.51-196.65-89.80-
Return on Equity-1,459.01-13,215.59-394.32-136.93-113.03-182.26-231.96-114.45-
Return on Invested Capital-1,244.76-984.84--157.91-76.24-179.47-163.38-56.93-
Quick Ratio1.161.120.832.2716.168.216.775.680.00
Current Ratio1.161.120.832.2716.168.216.775.680.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-15.80-31.57-17.70-16.58-15.92-10.15-8.34-7.36-1.05
Depreciation0.040.040.060.110.090.030.030.030.02
Other Funds (Non Cash)-0.3917.114.738.280.543.182.561.08-0.00
Funds from Operations-16.15-14.43-12.91-8.19-15.29-6.94-5.75-6.26-1.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.280.470.61-0.181.620.341.050.160.23
Cash from Operating Activities-18.43-13.96-12.29-8.37-13.66-6.60-4.70-6.10-0.80
Capital Expenditures0.000.000.00-0.10-0.02-0.04-0.000.00-0.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.040.070.040.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.040.070.040.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.040.070.04-0.10-0.02-0.04-0.000.00-0.10
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock71.1917.0816.640.6417.4515.645.857.422.77
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock71.1917.0816.640.6417.4515.645.857.422.77
Proceedsfrom Stock Options65.5411.4415.610.0015.0813.755.627.422.77
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities71.1517.0116.570.5717.3915.645.857.422.77
Exchange Rate Effect-1.420.31-0.22-0.090.530.03-0.03-0.090.04
Net Change in Cash51.343.444.09-8.004.249.041.111.231.91
Free Cash Flow-18.43-13.96-12.29-8.37-13.68-6.60-4.70-6.10-0.80
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments61.1711.8716.118.1911.5310.11
Short Term Receivables0.140.070.060.250.070.23
Inventories0.000.000.000.000.000.00
Other Current Assets1.962.660.470.660.480.35
Total Current Assets63.3014.6016.639.0912.0810.69
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.270.280.300.300.320.31
Other Assets0.000.000.000.000.000.00
Total Assets63.5714.8816.939.4012.4011.00
Short Term Debt Incl. Current Port. of LT Debt0.000.000.010.020.040.06
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities30.5610.9114.3911.4913.039.98
Total Current Liabilities30.5610.9114.4011.5113.0810.04
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities30.5610.9114.4011.5113.0810.04
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity33.023.972.54-2.11-0.670.97
Total Shareholders Equity33.023.972.54-2.11-0.670.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity33.023.972.54-2.11-0.670.97
Total Liabilities & Stockholders Equity63.5714.8816.939.4012.4011.00
Book Value Per Share0.310.050.03-0.03-0.010.01
Tangible Book Value Per Share0.310.050.03-0.03-0.010.01
Price to Book Ratio4.29118.37-194.44-255.41184.8120.66
Return on Assets-41.42-232.67-207.62-142.18-117.82-107.03
Return on Equity-97.30-1,220.04-1,462.20-790.66-456.91-248.16
Return on Invested Capital23.64-30.76-760.82---285.02
Quick Ratio2.071.341.160.790.921.06
Current Ratio2.071.341.160.790.921.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income7.63-1.22-19.14-3.07-6.67-2.75
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)-11.15-3.4214.81-0.623.33-0.38
Funds from Operations-3.51-4.64-4.32-3.68-3.33-3.12
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.58-1.34-0.15-0.210.580.25
Cash from Operating Activities-4.09-5.98-4.47-3.89-2.75-2.87
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-0.000.010.020.020.020.02
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments-0.000.010.020.020.020.02
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.000.010.020.020.020.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock56.432.0311.960.773.480.91
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock56.432.0311.960.773.480.91
Proceedsfrom Stock Options55.68-0.049.95-0.050.740.82
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities56.432.0311.940.753.460.89
Exchange Rate Effect-1.58-0.070.24-0.010.070.02
Net Change in Cash50.77-4.027.73-3.140.80-1.95
Free Cash Flow-4.09-5.98-4.47-3.89-2.75-2.87

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.41%4.9M89.8M505.78K
2026-10-155.66%5.1M89.8M530.06K
2026-09-306.51%5.8M89.6M588.55K
2026-09-156.13%5.5M89.6M653.86K
2026-08-316.07%5.4M89.7M712.36K
2026-08-146.34%5.3M84.2M975.86K
2026-07-318.45%5.4M64.4M936.97K
2026-07-157.00%4.5M64.5M874.64K
2026-06-306.33%4.1M64.0M777.21K
2026-06-155.39%3.5M64.0M641.32K
2026-05-294.89%3.1M63.1M515.13K
2026-05-152.45%1.6M63.9M168.24K
2026-04-302.31%1.5M63.6M163.00K
2026-04-152.04%1.3M62.5M162.03K
2026-03-312.28%1.4M62.5M142.02K
2026-03-132.16%1.4M62.5M139.09K
2026-02-272.10%1.3M62.5M154.16K
2026-02-132.11%1.3M62.5M162.00K
2026-01-302.04%1.3M62.2M153.19K
2026-01-151.96%1.2M62.2M143.00K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.093.2282,7380.000.169-0.0100.001
call5.000.000.050.075.1266050.000.124-0.0120.000
call7.500.000.100.506.1273.000.000.111-0.0130.000
put2.500.551.600.708.35667.000.00-0.831-0.0090.001
put5.001.606.003.200.0000.000.00-0.877-0.0120.000
put7.503.608.500.000.0000.000.00-0.890-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-166-K/A2026-08-13SEC
2026-10-1640-F/A2025-12-31SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-25SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-07-02SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-01SEC
2026-05-26EFFECTEffectiveness filing by commission orderSEC
2026-05-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-26SEC
2026-05-26SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-05-26F-XFor appointment of agent for service of process by issuers registering securities (if filed on Form F-8, F-9, F-10 or F-80, or registering securities or filing periodic reports on Form 40-F, or by any person filing certain tender offer documents, or by anSEC
2026-05-26F-10Registration statement for securities of certain Canadian issuers under the Securities Act of 1933SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-22SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-05-21SUPPLVoluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuersSEC
2026-05-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-18SEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC
2026-05-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-27SEC
2026-03-3140-FRegistration Statement Pursuant to Section 12 of the Securities Exchange Act of 1934 or Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 19342025-12-31SEC
2026-03-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-13SEC
2026-02-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-13SEC
2026-02-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-10SEC
2026-01-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-01-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-08SEC
2026-01-07EFFECTEffectiveness filing by commission orderSEC
2026-01-07CERTSEC
2026-01-078-A12BSEC
2026-01-07F-10/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Empery Asset Management, LP4.87%
Rock Springs Capital Management LP1.47%
DAFNA Capital Management LLC1.28%
Ghisallo Capital Management LLC1.22%
ARMISTICE CAPITAL, LLC0.82%
VALLEY FORGE INVESTMENT CONSULTANTS INC ADV0.78%
LMR Partners LLP0.73%
MARSHALL WACE, LLP0.53%
Stonepine Capital Management, LLC0.33%
JANE STREET GROUP, LLC0.33%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.06%

OakChart. NGEN. Cached 15 minutes.

Some panels did not load: insider.